Bachem stock gains as SPI health care specialist approaches 52-week high

Bachem stock is trading close to its 52-week high on the SIX Swiss Exchange, supported by recent share price gains and solid fundamentals from the latest reporting period.

Bachem Holding AG (ISIN CH0012530207) stock is trading strongly on the SIX Swiss Exchange, with recent data showing levels near its 52-week high as of September 2, 2026, and a closing price of 74.35 CHF according to Morningstar.

Share price strength on SIX and German venues

According to a quote overview compiled by Morningstar and cited by ad-hoc-news.de, Bachem shares closed at 74.35 CHF on the SIX Swiss Exchange on September 2, 2026, only around 1.65 CHF below a reported 52-week high of 76.00 CHF, underscoring the stock’s strong performance this year.

Same-day trading data reported by finanzen.ch shows that on September 3, 2026, Bachem shares rose intraday by around 2.6 percent to 78.75 CHF in the SIX SX session, after starting the trading day at 77.65 CHF, placing the stock among the notable gainers in the SPI index.

For investors following Bachem via German venues, finanzen.net quotes the Bachem share at 78.00 CHF, corresponding to about 83.65 EUR on Tradegate as of September 3, 2026, where the stock shows a daily gain of 1.83 percent, reflecting continued demand beyond the home market.

DACH anchor via SPI index and German trading

The current price development also highlights Bachem’s role in the Swiss equity landscape. As noted in the ad-hoc-news.de corporate news overview, Bachem belongs to the SPI segment as a specialized health care and biotechnology value, with a market capitalization described in the billions of CHF as of September 2, 2026 based on Morningstar’s data.

In addition to the listing on SIX Swiss Exchange under the ticker BANB, Bachem stock is available to DACH investors via German platforms such as Tradegate and Stuttgart, where finanzen.net reports recent trading at around 83.65 EUR on September 3, 2026, providing an accessible route for euro-based investors to participate in the peptide manufacturer’s equity story.

Peptide-based pharmaceuticals as core business

Bachem is known as a specialist in peptide-based active pharmaceutical ingredients and related technologies, supplying pharmaceutical and biotech companies with complex molecules used in therapeutics and research. The company focuses on high-quality custom synthesis and catalog products, which serve as critical components in modern drug development and clinical programs.

Peptide demand tends to track structural growth in targeted therapies and innovative treatments, meaning Bachem’s order book and capacity investments are closely watched by investors for signals on medium-term revenue potential. While detailed figures from the latest quarter or half-year are not explicitly stated in the accessible same-day sources, the current valuation and near-high trading levels indicate that the market prices in continued business momentum in its core peptide operations.

Closing price context for investors

For the latest completed trading day, Morningstar’s overview cited by ad-hoc-news.de shows Bachem stock closing at 74.35 CHF on September 2, 2026 on SIX Swiss Exchange, with an intraday range between 73.80 CHF and 76.00 CHF, placing the closing level only slightly below the identified 52-week high of 76.00 CHF.

This puts the stock’s recent intraday print of 78.75 CHF on September 3, 2026 from finanzen.ch above the previously reported 52-week high level, illustrating how the recent upward move has pushed Bachem into a new price zone where investors will pay particular attention to upcoming company news and potential revisions to consensus expectations.

Bachem stock key data

• Company: Bachem Holding AG
• ISIN: CH0012530207
• Ticker: BANB
• Trading venue: SIX Swiss Exchange
• Price (as of September 3, 2026): 78.75 CHF
• Market capitalization: Billions of CHF (as of September 2, 2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: SPI